Synergistic Signaling of KRAS and Thyroid Hormone Receptor β Mutants Promotes Undifferentiated Thyroid Cancer through MYC Up-Regulation

Neoplasia (United States)

Volumn 16, Issue 9, 2014, Pages 757-769

  Zhu, Xuguang ^a   Zhao, Li ^a   Park, Jeong Won ^a   Willingham, Mark C ^a   Cheng, Sheue yann ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925510378     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.08.003     Document Type: Article

References (49)

1. Nikiforov YE, Nikiforova MN Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011, 7(10):569-580.
2. Miller KA, Yeager N, Baker K, Liao XH, Refetoff S, Di Cristofano A Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res 2009, 69(8):3689-3694.
3. Franco AT, Malaguarnera R, Refetoff S, et al. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A 2011, 108(4):1615-1620.
4. Kaneshige M, Kaneshige K, Zhu X, et al. Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci U S A 2000, 97(24):13209-13214.
5. Suzuki H, Willingham MC, Cheng SY Mice with a mutation in the thyroid hormone receptor β gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 2002, 12(11):963-969.
6. Parrilla R, Mixson AJ, McPherson JA, McClaskey JH, Weintraub BD Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" regions of the ligand binding domain. J Clin Invest 1991, 88(6):2123-2130.
7. Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007, 13(4):1161-1170.
8. Furuya F, Hanover JA, Cheng SY Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone β receptor. Proc Natl Acad Sci U S A 2006, 103(6):1780-1785.
9. Lu C, Zhao L, Ying H, Willingham MC, Cheng SY Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. Endocrinology 2010, 151(4):1929-1939.
10. Guigon CJ, Zhao L, Lu C, Willingham MC, Cheng SY Regulation of β-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol Cell Biol 2008, 28(14):4598-4608.
11. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001, 15(24):3243-3248.
12. Kusakabe T, Kawaguchi A, Kawaguchi R, Feigenbaum L, Kimura S Thyrocyte-specific expression of Cre recombinase in transgenic mice. Genesis 2004, 39(3):212-216.
13. Furumoto H, Ying H, Chandramouli GV, Zhao L, Walker RL, Meltzer PS, Willingham MC, Cheng SY An unliganded thyroid hormone β receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol 2005, 25(1):124-135.
14. Zhu XG, McPhie P, Cheng SY Differential sensitivity of thyroid hormone receptor isoform homodimers and mutant heterodimers to hormone-induced dissociation from deoxyribonucleic acid: its role in dominant negative action. Endocrinology 1997, 138(4):1456-1463.
15. Zhao L, Zhu X, Won Park J, Fozzatti L, Willingham M, Cheng SY Role of TSH in the spontaneous development of asymmetrical thyroid carcinoma in mice with a targeted mutation in a single allele of the thyroid hormone-β receptor. Endocrinology 2012, 153(10):5090-5100.
16. Nitsch R, Di Dato V, di Gennaro A, de Cristofaro T, Abbondante S, De Felice M, Zannini M, Di Lauro R Comparative genomics reveals a functional thyroid-specific element in the far upstream region of the PAX8 gene. BMC Genomics 2010, 11:306.
17. Rivas M, Santisteban P TSH-activated signaling pathways in thyroid tumorigenesis. Mol Cell Endocrinol 2003, 213(1):31-45.
18. Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol 2008, 21(2):192-200.
19. Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 1994, 54(17):4744-4749.
20. Shachaf CM, Kopelman AM, Arvanitis C, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004, 431(7012):1112-1117.
21. Henriksson M, Luscher B Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res 1996, 68:109-182.
22. Kurihara T, Ikeda S, Ishizaki Y, et al. Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. Thyroid 2004, 14(12):1020-1029.
23. Smallridge RC, Marlow LA, Copland JA Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009, 16(1):17-44.
24. Reynolds C, Roderick JE, Labelle JL, et al. Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia. Leukemia 2014, (advance online publication 25 March 2014).
25. Salmanidis M, Brumatti G, Narayan N, et al. Hoxb8 regulates expression of microRNAs to control cell death and differentiation. Cell Death Differ 2013, 20(10):1370-1380.
26. Grandori C, Cowley SM, James LP, Eisenman RN The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000, 16:653-699.
27. Furuya F, Lu C, Willingham MC, Cheng SY Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 2007, 28(12):2451-2458.
28. Guigon CJ, Zhao L, Willingham MC, Cheng SY PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene 2009, 28(4):509-517.
29. Kim HK, Kim D, Yoo EH, et al. A case of resistance to thyroid hormone with thyroid cancer. J Korean Med Sci 2010, 25(9):1368-1371.
30. Ramos-Prol A, Antonia Pérez-Lázaro M, Isabel del Olmo-García M, León-de Zayas B, Moreno-Macián F, Navas-de Solis S, Merino-Torres JF Differentiated thyroid carcinoma in a girl with resistance to thyroid hormone management with triiodothyroacetic acid. J Pediatr Endocrinol Metab 2013, 26(1-2):133-136.
31. Xifra G, Mauri S, Gironès J, Rodriguez Hermosa JI, Oriola J, Ricart W, Fernández-Real JM Multiple Hürthle cell adenomas in a patient with thyroid hormone resistance. Endocrinol Diabetes Metab Case Rep 2013, 2013:130032.
32. Paragliola RM, Lovicu RM, Locantore P, Senes P, Concolino P, Capoluongo E, Pontecorvi A, Corsello SM Differentiated thyroid cancer in two patients with resistance to thyroid hormone. Thyroid 2011, 21(7):793-797.
33. Ünlütürk U, Sriphrapradang C, Erdoğan MF, Emral R, Güldiken S, Refetoff S, Güllü S Management of differentiated thyroid cancer in the presence of resistance to thyroid hormone and TSH-secreting adenomas: a report of four cases and review of the literature. J Clin Endocrinol Metab 2013, 98(6):2210-2217.
34. Weinert LS, Ceolin L, Romitti M, Camargo EG, Maia AL Is there a role for inherited TRβ mutation in human carcinogenesis? [corrected]. Arq Bras Endocrinol Metabol 2012, 56(1):67-71.
35. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463(7283):899-905.
36. Demeterco C, Itkin-Ansari P, Tyrberg B, Ford LP, Jarvis RA, Levine F c-Myc controls proliferation versus differentiation in human pancreatic endocrine cells. J Clin Endocrinol Metab 2002, 87(7):3475-3485.
37. Vaqué JP, Fernández-García B, Garcia-Sanz P, et al. c-Myc inhibits Ras-mediated differentiation of pheochromocytoma cells by blocking c-Jun up-regulation. Mol Cancer Res 2008, 6(2):325-339.
38. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451(7175):141-146.
39. Takahashi K, Yamanaka S Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126(4):663-676.
40. Joseph B, Ji M, Liu D, Hou P, Xing M Lack of mutations in the thyroid hormone receptor (TR) α and β genes but frequent hypermethylation of the TRβ gene in differentiated thyroid tumors. J Clin Endocrinol Metab 2007, 92(12):4766-4770.
41. D'Cruz CM, Gunther EJ, Boxer RB, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001, 7(2):235-239.
42. Soucek L, Whitfield J, Martins CP, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008, 455(7213):679-683.
43. Soucek L, Whitfield JR, Sodir NM, Massó-Vallés D, Serrano E, Karnezis AN, Swigart LB, Evan GI Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev 2013, 27(5):504-513.
44. Koh CM, Gurel B, Sutcliffe S, et al. Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. Am J Pathol 2011, 178(4):1824-1834.
45. Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas MS, Gudkov AV, Prochownik EV, Nikiforov MA c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 2008, 27(13):1905-1915.
46. Arvanitis C, Felsher DW Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol 2006, 16(4):313-317.
47. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature 2010, 468(7327):1067-1073.
48. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146(6):904-917.
49. Loven J, Hoke HA, Lin CY, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153(2):320-334.